Kimelman & Baird, LLC Gilead Sciences, Inc. Transaction History
Kimelman & Baird, LLC
- $1.26 Trillion
- Q4 2024
A detailed history of Kimelman & Baird, LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Kimelman & Baird, LLC holds 200 shares of GILD stock, worth $20,662. This represents 0.0% of its overall portfolio holdings.
Number of Shares
200
Previous 200
-0.0%
Holding current value
$20,662
Previous $16.8 Million
10.17%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding GILD
# of Institutions
2,030Shares Held
1.01BCall Options Held
10MPut Options Held
8.9M-
Black Rock Inc. New York, NY121MShares$12.5 Billion0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA116MShares$11.9 Billion0.19% of portfolio
-
Capital World Investors Los Angeles, CA76.5MShares$7.91 Billion1.03% of portfolio
-
Capital Research Global Investors Los Angeles, CA61.8MShares$6.38 Billion1.12% of portfolio
-
State Street Corp Boston, MA60.2MShares$6.22 Billion0.21% of portfolio
About GILEAD SCIENCES, INC.
- Ticker GILD
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,253,369,984
- Market Cap $129B
- Description
- Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...